The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
about
Cardiovascular safety of anti-diabetic drugsTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsElevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brainAdenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapyMetformin and metabolic diseases: a focus on hepatic aspectsFarnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialTreatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.AMPK activation: a therapeutic target for type 2 diabetes?Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Rare mutations of peroxisome proliferator-activated receptor gamma: frequencies and relationship with insulin resistance and diabetes risk in the mixed ancestry population from South Africa.Screening for bioactive metabolites in plant extracts modulating glucose uptake and fat accumulationPioglitazone normalizes insulin signaling in the diabetic rat retina through reduction in tumor necrosis factor α and suppressor of cytokine signaling 3.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Pioglitazone restores IGFBP-3 levels through DNA PK in retinal endothelial cells cultured in hyperglycemic conditions.Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study.Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinomaDoes enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot studyIntegrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic ValueCurrent clinical evidence on pioglitazone pharmacogenomics.PPARs and Mitochondrial Metabolism: From NAFLD to HCC.Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.Anti-inflammatory Strategies to Prevent Diabetic Cardiovascular Disease.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.The pharmacological management of NAFLD in children and adolescents.The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.Diabetes in Cushing Disease.Pioglitazone alters monocyte populations and stimulates recent thymic emigrants in the BBDZR/Wor type 2 diabetes rat model.The role of local renin-angiotensin system on high glucose-induced cell toxicity, apoptosis and reactive oxygen species production in PC12 cellsNAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?Diabetes Mellitus Secondary to Cushing's Disease.Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysisObesity and nonalcoholic fatty liver disease: current perspectivesEffects of Three Thiazolidinediones on Metabolic Regulation and Cold-Induced Thermogenesis
P2860
Q26741082-9D43669B-48F2-4621-9C0B-4D9D7FE59915Q26751258-1AAF070B-46D3-4416-9E86-677F17D7BC64Q27003253-0D868C56-DB37-4D63-A585-C093A513B1F2Q28068120-C8687C1A-22DD-49D3-9775-BACFB139C136Q28082736-E84C27ED-79BD-4849-B818-71E68B5B1FD7Q28253122-97E250B3-19D0-46F7-8B0C-E29F6B4AB40BQ33802278-6719EF35-AB65-4C9C-9C92-B85BC8A9E988Q33824564-F75831D2-5AEF-4B8F-820F-E1308B47ACFDQ33887783-B69C2451-89F1-422A-B05C-B042B8AA6095Q34114146-1AB1AB6C-5B33-4A78-98CF-B32C4BB46C22Q34183013-900BC2B6-78F5-40E1-B02C-57E1A33912A2Q34249131-CC27224B-7386-4AFD-BD56-36E8BF95B056Q34315432-0FC58275-14FE-4007-BC24-34F409CFBE26Q34956067-B2452CD1-90EB-44CF-BA52-A327875002F3Q36428446-81BFEDFE-1A0A-429F-8AAA-14403A3D471CQ37031730-9A6AA5F9-22CF-4F76-ABF2-5334F7BF1879Q37200737-C34042FB-BBBA-447D-A559-549819236217Q37276814-6541241D-BEDC-4A92-8187-CDB570ADB0C2Q37342358-0E5775CC-1381-4121-BD1A-0352F08830F2Q37575571-8910C36C-2750-4778-8C20-E8E42CB72C86Q37671303-76C52E35-DDF4-4F6A-9AEC-BB987F957022Q38366821-D5E49F3F-C524-430E-9AED-0385B43BAC82Q38641190-484302FF-3079-477F-95F6-D41AF441C419Q38643266-E22CA2DA-0B0C-492A-9845-3916F68B2D4DQ38676257-A28F4A46-D5B8-4B84-AB10-6E28E29C5ACCQ39212408-6D7244AE-D865-4D52-80EF-49743269E3F2Q41767005-EF4F8D71-E523-4D3E-90B2-39D59A6DB7D9Q41895132-B18BD76B-A951-4ADB-9972-0AE8A5A53685Q54232638-8730F437-C560-4731-ABE4-F64AB1D11C3FQ55425212-4A29A0B1-995B-4CAB-8838-6880C3DFED39Q56343202-BBFC35D6-246E-4C37-8814-703A177EE782Q57069715-8CA3899C-F15F-4A22-8390-48B4E24897C3Q58703696-442A58DC-1059-427B-A96B-ECBEACD43C5E
P2860
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
@en
type
label
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
@en
prefLabel
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
@en
P2093
P2860
P1476
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus
@en
P2093
Kathya Rivera
Kenneth Cusi
Romina Lomonaco
P2860
P2888
P304
P356
10.1007/S11892-013-0378-8
P50
P577
2013-06-01T00:00:00Z
P6179
1014294928